Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2014	Mar. 30, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MELA
Entity Common Stock, Shares Outstanding		7,525,146
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 16,544,970

BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 11,434	$ 3,783
Accounts receivable (net of allowance of $95 and $46 as of December 31, 2014 and 2013, respectively)	220	57
Inventory (net of reserve $1,409 and $325 as of December 31, 2014 and 2013, respectively) (See Note 4)	5,275	5,631
Prepaid expenses and other current assets	274	880
Total Current Assets	17,203	10,351
Property and equipment, net (See Note 5)	1,961	3,691
Patents and trademarks, net	37	42
Deferred financing costs	821	0
Other assets	48	48
Total Assets	20,070	14,132
Current Liabilities:
Accounts payable (includes related parties of $74 and $33 as of December 31, 2014 and 2013, respectively)	1,240	1,479
Accrued expenses (includes related parties of $0 and $48 as of December 31, 2014 and 2013, respectively)	842	844
Deferred revenue	43	244
Warrant liability (See Note 10)	499	3,017
Other current liabilities	62	68
Total Current Liabilities	2,686	5,652
Long Term Liabilities:
Deferred revenue	27	64
Deferred rent	80	120
Senior secured convertible debentures (net of discount of $8,410 at December 31, 2014)	5,001	0
Total Long Term Liabilities	5,108	184
Total Liabilities	7,794	5,836
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity:
Series B convertible preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 11,787 and 0 at December 31, 2014 and 2013, respectively	1	0
Common stock - $0.001 par value; authorized 50,000,000 shares: Issued and outstanding 6,037,232 and 4,750,160 shares at December 31, 2014 and 2013, respectively.	6	5
Additional paid-in capital	194,562	176,439
Accumulated deficit	(182,293)	(168,148)
Total Stockholders' Equity	12,276	8,296
Total Liabilities and Stockholders' Equity	$ 20,070	$ 14,132

BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Allowance for accounts receivable, current	$ 95	$ 46
Inventory, net of reserves	1,409	325
Accounts payable, related parties	74	33
Accrued expenses, related parties	0	48
Senior secured convertible debentures, discount	$ 8,410
Preferred Stock, Par or Stated Value Per Share	$ 0.10	$ 0.10
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	11,787	0
Preferred Stock, Shares Outstanding	11,787	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Shares, Issued	6,037,232	4,750,160
Common Stock, Shares, Outstanding	6,037,232	4,750,160

STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net revenues	$ 915	$ 536
Cost of revenue	4,935	4,341
Gross profit	(4,020)	(3,805)
Operating expenses:
Research and development	1,641	3,782
Selling, general and administrative	10,961	15,536
Impairment of long-lived assets	0	1,011
Total operating expenses	12,602	20,329
Operating loss	(16,622)	(24,134)
Other income (expenses):
Interest income	8	8
Interest expense	(2,380)	(564)
Change in fair value of warrant liability	8,103	(296)
Write-off of unamortized loan costs	0	(983)
Gain on sale of fixed assets	16	0
Registration rights liquidated damages	(3,420)	0
Other income, net	150	21
Nonoperating Income (Expense)	2,477	(1,814)
Net loss	(14,145)	(25,948)
Deemed dividend related to beneficial conversion feature on convertible preferred stock	(1,887)	0
Net loss attributable to common stockholders	$ (16,032)	$ (25,948)
Basic and diluted net loss per common share (in dollars per share)	$ (3.03)	$ (6.05)
Basic and diluted weighted average number of common shares outstanding (in shares)	5,295,929	4,289,450

STATEMENT OF STOCKHOLDERS' EQUITY (USD $) In Thousands, except Share data	Total	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]
Balance at Dec. 31, 2012	$ 13,975	$ 156,172	$ (142,200)	$ 3	$ 0	$ 0
Balance (in shares) at Dec. 31, 2012				3,220,000	0	0
Issuance of shares of common stock in connection with a public offering (net of issuance costs of $1,025)	15,725	15,724	0	1	0	0
Issuance of shares of common stock in connection with a public offering (net of issuance costs of $1,025) (in shares)				1,081,000	0	0
Issuance of shares of common stock and warrants in connection with an October 2013 private placement (net of issuance costs of $3,426)	2,573	2,572	0	1	0	0
Issuance of shares of common stock and warrants in connection with an October 2013 private placement (net of issuance costs of $3,426) (in shares)				423,000	0	0
Warrants issued in connection with loans payable	652	652	0	0	0	0
Warrants issued in connection with loans payable (in shares)				0	0	0
Exercise of options	18	18	0		0	0
Exercise of options (in shares)	1,806			2,000	0	0
Share-based compensation expense	1,301	1,301	0	0	0	0
Share-based compensation expense (in shares)				24,000	0	0
Net loss	(25,948)	0	(25,948)	0	0	0
Balance at Dec. 31, 2013	8,296	176,439	(168,148)	5	0	0
Balance (in shares) at Dec. 31, 2013				4,750,000	0	0
Issuance of Series A convertible preferred stock and common stock in connection with the February 2014 private placement (net of issuance costs of $992)	11,458	11,457	0	0	1	0
Issuance of Series A convertible preferred stock and common stock in connection with the February 2014 private placement (net of issuance costs of $992) (in shares)				20,000	12,000	0
Issuance of warrants in connection with the February 2014 private placement	(5,585)	(5,585)	0	0	0	0
Issuance of warrants in connection with the February 2014 private placement (in shares)				0	0	0
Issuance of Series B convertible preferred stock in connection with the July 2014 private placement	1		0	0	0	1
Issuance of Series B convertible preferred stock in connection with the July 2014 private placement (in shares)				0	0	12,000
Expenses related to the issuance of Series B convertible preferred stock in connection with the July 2014 private placement	(103)	(103)
Warrants and beneficial conversion feature issued with senior secured debentures	10,353	10,353	0	0	0	0
Redemption of Series A convertible preferred stock in connection with the July 2014 private placement	(1)	0	0	0	(1)	0
Redemption of Series A convertible preferred stock in connection with the July 2014 private placement (in shares)				0	(12,000)	0
Beneficial conversion feauture related to Series B convertible preferred stock	0	(1,887)	0	0	0	1,887
Accretion of discount on Series B convertible preferred stock	0	1,887	0	0	0	(1,887)
Conversion of 0.5 shares of Series B convertible preferred stock	0	0		0	0	0
Conversion of 0.5 shares of Series B convertible preferred stock (in shares)				200,000	0	(1,000)
Conversion of $1,589 in convertible debentures	1,589	1,588	0	1	0	0
Conversion of $1,589 in convertible debentures (in shares)				620,000	0	0
Exercise of prefunded warrants	0	0	0	0	0	0
Exercise of prefunded warrants (in shares)				434,000	0	0
Issuance of shares of common stock in connection with a public offering (net of issuance costs of $1,025) (in shares)						12,300,000
Exercise of options (in shares)	0
Share-based compensation expense	413	413	0	0	0	0
Share-based compensation expense (in shares)				13,000	0	0
Net loss	(14,145)	0	(14,145)	0	0	0
Balance at Dec. 31, 2014	$ 12,276	$ 194,562	$ (182,293)	$ 6	$ 0	$ 1
Balance (in shares) at Dec. 31, 2014				6,037,000	0	11,000

STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Issuance Cost Of Common Stock And Warrants	$ 992
Debt Conversion, Converted Instrument, Amount		652
Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities	500
Convertible Debenture [Member]
Debt Conversion, Converted Instrument, Amount	1,589
Common Stock [Member]
Issuance Cost Of Common Stock In Connection With Public Offering		1,025
Issuance Cost Of Common Stock And Warrants		$ 3,426

- Definition

Number of shares issued during the period as a result of the conversion of convertible securities.

+ References+ Details

STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (14,145)	$ (25,948)
Adjustments to reconcile net loss:
Write-off of unamortized loan costs	0	983
Depreciation and amortization	1,790	2,439
Impairment of long-lived assets	0	1,011
Bad debt expense	52	46
Write-off of unamortized financing costs	0	41
Share-based compensation expense	413	1,301
Amortization of deferred financing costs	191	250
Amortization of debt discount	1,943	0
Change in fair value of warrant liability	(8,103)	296
Inventory reserve	1,084	325
Gain on sale of fixed assets	(16)	0
Changes in operating assets and liabilities:
Accounts receivable	(215)	77
Inventory	(784)	121
Prepaid expenses and other current assets	606	86
Other assets	0	36
Accounts payable and accrued expenses	(241)	(484)
Other current liabilities	(6)	27
Deferred rent	(40)	(24)
Deferred revenue	(238)	4
Net cash used in operating activities	(17,709)	(19,413)
Cash flows from investing activities:
Purchases of property and equipment	0	(5,188)
Proceeds from the sale of fixed assets	17	0
Net cash provided by (used in) investing activities	17	(5,188)
Cash flows from financing activities:
Net proceeds from private placements/public offerings	11,458	21,174
Proceeds from long-term debt	15,000	6,000
Expenses related to long-term debt	(1,012)	(245)
Expenses related to issuance of Series B convertible preferred stock	(103)	0
Repayment of long-term debt	0	(6,425)
Proceeds from exercise of stock options	0	18
Net cash provided by financing activities	25,343	20,522
Net increase (decrease) in cash and cash equivalents	7,651	(4,079)
Cash and cash equivalents at beginning of period	3,783	7,862
Cash and cash equivalents at end of period	11,434	3,783
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	116	0
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Conversion of convertible preferred stock into common stock	513	0
Conversion of senior secured convertible debentures into common stock	1,589	0
Recognition of debt discount on senior secured convertible debentures	5,788	0
Recognition of beneficial conversion feature on senior secured convertible debentures	4,565	0
Exchange of series A convertible preferred stock for series B convertible preferred stock	12,300	0
Reclassification of warrant liability to stockholders equity	0	652
Reclassification of MelaFind components between property and equipment and inventory	$ 0	$ 5,402

Principal Business Activities

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Principal Business Activities

1. Principal Business Activities

Organization and Business

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company dedicated to designing and developing innovative software-driven technology for the early detection and prevention of skin cancer. The Company is focused on the commercialization of its flagship product, the MelaFind^® System, or MelaFind, as well as the further design and development of this technology. MelaFind is a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of melanoma. The system features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, “trained” by our proprietary database of melanomas and benign lesions. This result provides information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

MelaFind’s components include:

•

a hand-held imager, which employs high precision optics and multi-spectral illumination (multiple wavelengths of light);

•

a proprietary database of pigmented skin lesions, believed to be the largest prospective database to date in the U.S.; and

•

lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

In November 2011, the Company received a Pre-Market Approval, or PMA, from the U.S. Food and Drug Administration (“FDA”) for MelaFind, having already received Conformité Européenne (“CE”) Mark approval in September 2011. On March 7, 2012, the Company installed the first commercial MelaFind System. The Company initially marketed the MelaFind System primarily to aesthetic dermatologists through a lease program in which users paid an upfront placement fee and periodic fees for use. In 2013, because the launch objectives were not realized, the Company reviewed its marketing strategy. Revenues amounting to $536 and $278 in 2013 and 2012, respectively, did not meet expectations, and due to the nature of the lease agreements the Company continued to record high cost of sales. The Company implemented a significant cost reduction program in 2013 that affected all areas of its business, and which continued throughout 2014. As a result of this strategy review in 2013, the Company undertook several steps that it believes will significantly improve MelaFind’s commercial acceptance by: 1) changing its business model from solely a rental-based model to include a capital sales option; 2) refocusing its marketing efforts on medical dermatology, and particularly those dermatologists who treat patients at high risk for melanoma; and 3) beginning the process of obtaining a coverage determination from the Centers for Medicare & Medicaid Services (“CMS”), the federal agency that administers Medicare, in order to obtain reimbursement by Medicare and ultimately by private insurers for the use of MelaFind. During 2014 the Company made significant strides in each of these areas, although it anticipates that it will require a few years of continued effort before the success of this strategy can be assessed. The Company anticipates that the insurance reimbursement process could take several years to complete.

In July 2014, the Company announced that it took the first step in the process of obtaining insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (“MSDSLA”) procedure that is performed by dermatologists utilizing the MelaFind system as an aid in the detection of melanoma. The Company submitted an application for a CPT code, which is necessary for Medicare Part B reimbursement by the CMS. On March 9, 2015, the February 2015 CPT^® Editorial Summary of Panel Actions was posted to the website of the American Medical Association (the “AMA”). The CPT Editorial Panel accepted the addition of Category III codes 039XX1T and 039XX2T to report MSDSLA of atypical cutaneous lesions, which applies to the MelaFind System. Barring any further action by the Panel, the Company expects that these codes will be posted to the AMA CPT website by July 1, 2015 with an effective date of January 1, 2016 and will provide the basis for pursuing third party and CMS insurance coverage for MelaFind. The Company plans to commence efforts to obtain reimbursement from private insurers, which could take several years to complete.

Until the Company obtains insurance reimbursement from the CMS and private insurers, it expects that revenues will not be sufficient to cover operating and other expenses. The Company’s financial success will depend on a number of factors, primary among which is the ability to sell MelaFind systems, increase the penetration with dermatologists, encourage the usage of these systems, and control costs. Currently, the Company cannot determine when it will have sufficient revenues to cover continuing developmental costs, manufacturing, marketing and other operational expenses.

Basis of Presentation

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

2. Basis of Presentation

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Liquidity and Going Concern

The Company has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As the result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. In mid-year 2013, management put in place a cost reduction program that included staff reductions, the elimination or deferral of all nonessential projects and activities and the scaling back or discontinuance of general corporate activities (referred to as “Cost Reduction Plan”) to preserve liquidity. In addition, in February 2014, the Company raised net proceeds of approximately $11,458 from the sale of convertible preferred stock, common stock and warrants and in July 2014, the Company raised proceeds of approximately $15,000 from the sale of senior secured convertible debentures, convertible preferred stock and warrants to strengthen the Company’s financial position.

The Company continues to incur net losses. These net losses have had a significant negative impact on the Company’s working capital and financial position and may impact its future ability to meet its obligations in the ordinary course of business. As a result, management believes that, even with cash and cash equivalents held at December 31, 2014, and estimated revenue, there is significant doubt about its ability to continue as a going concern. The Company continues to assess the effects of its previously announced Cost Reduction Plan and is prepared to further reduce various operational costs as necessary. Although the Company has no specific arrangements or plans, the Company will need additional capital during the next 12 months.

The Company expects to incur additional medical, marketing and sales expenses as well as additional contract manufacturing and inventory costs in the future that will require additional funding. As a result, the Company expects to continue to incur operating losses for the foreseeable future and cannot determine at this time when it will generate any significant revenues. As of December 31, 2014, the Company’s cash and cash equivalents was approximately $11,434. If existing cash is insufficient to satisfy its liquidity requirements, or if it develops additional products, the Company may seek to sell additional debt or equity securities. If additional funds are raised through the issuance of debt securities, these securities would have rights senior to those associated with the Company’s common stock and could contain covenants that would restrict the Company’s operations. Any additional financing may not be available in amounts or on terms acceptable to the Company, or at all. If the Company is unable to obtain any additional financing, it may be required to reduce the scope of, delay or eliminate some or all of planned product research development and commercialization activities, which could harm its business.

The Company’s financial statements are prepared in accordance with GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. In addition, as of December 31, 2014, the Company had an accumulated deficit of $182,293, had incurred a net loss for the year ended December 31, 2014, of $14,145 and had positive working capital of $14,517. Funding has been provided by related parties as well as new investors committed to making it possible to maintain, expand, and ensure the advancement of the MelaFind product. The Company has not made any adjustment to the financial statement regarding this uncertainty and continues to report as a going concern.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3. Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash equivalents primarily represent funds invested in money market funds, bank certificates of deposit and U.S. government debt securities with an original maturity of three months or less at the date of acquisition.

At year end, the Company has maintained bank balances in excess of insurance limits established by the Federal Deposit Insurance Corporation. The Company has not experienced any losses with respect to its placement of cash. Management believes the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.

Allowance for Doubtful Accounts

The Company establishes an allowance for uncollectible trade accounts receivable based on the age of outstanding invoices and management’s evaluation of collectability of outstanding balances. These provisions are established when the aging of outstanding amounts exceeds allowable terms and are re-evaluated at each quarter end for adequacy. In determining the adequacy of the provision, the Company considers known uncollectible or at risk receivables.

Inventories

Inventories consist of finished products and raw materials that are stated at the lower of cost (first-in, first-out) or market value. As of December 31, 2014 the reserve for obsolete inventory totaled $870. The Company reserves for specific inventory items that are no longer being used in the devices.

Throughout the year, the Company deferred repairs of certain of its MelaFind system units that it determined were unlikely to be sold during the next several periods. The Company estimated the cost to restore its system units to sellable condition and created a repair reserve amounting to $539 at December 31, 2014.

In mid 2013, because the Company’s initial launch objectives for the MelaFind system were not met, a significant cost reduction program was put into place and as part of a strategy review, in December 2013; the Company amended its business model from solely a rental-based model to include a capital sales option for the MelaFind device.

Business Segments

The Company’s operations are confined to one business segment: the design, development and commercialization of the MelaFind system.

Revenue recognition

The Company considers revenue to be earned when all of the following criteria are met: persuasive evidence a sales arrangement exists; delivery has occurred or services have been rendered; the price is fixed or determinable; and collectability is reasonably assured. The Company’s agreements with dermatologists regarding the MelaFind system combine the elements noted above with a future service obligation. In December 2013, the Company changed its business model from solely a rental-based model to include a capital sales option for its MelaFind product. Therefore, the Company will recognize revenues for product sales when title and risk of loss transfer to customers, which occurs upon completion of installation and training on the MelaFind system, when reliable estimates of sales allowances and warranties can be made, and collectability is reasonably assured. The Company will regularly review the information related to these estimates and adjust the reserves accordingly.

The Company also generated revenues from usage, based on the number of patient sessions or lesions examined, or a fixed monthly fee. The Company charges an initial installation fee for each MelaFind system which covers training, delivery, initial supplies, maintenance and the right to use MelaFind. In accordance with the accounting guidance regarding multiple-element arrangements, the Company allocates total contract consideration to each element based upon the relative standalone selling prices of each element, and recognizes the associated revenue for each element as delivery occurs or over the related service period, generally expected to be two years. Revenues associated with undelivered elements are deferred until delivery occurs or services are rendered. The significant judgments the Company makes relate to allocation of the contract consideration to each element whereby changes in standalone selling price could impact the amount of revenue recognized in a specific period and estimates of uncollectible accounts receivables.

In Germany, the typical contract with dermatologists calls for an installation or fixed monthly fee. Additionally, the Company typically charges a per patient usage charge. Revenue generated from German contracts is recognized when earned.

Cost of Revenue

Costs of revenue are associated with the costs of the Melafind system at time of sale and/or the costs to convert from a lease to a sale, warranty costs, repair costs, the placement costs of the MelaFind system in the doctor’s office on a lease, the cost of consumables delivered at installation, technical support costs and depreciation expense of the MelaFind system placed with the customer under lease which remains the property of the Company. Also, certain product quality and manufacturing overhead costs associated with supporting the contract manufacturers of MelaFind are allocated to costs of revenue.

Property and Equipment

For the year ended December 31, 2014 and 2013, the Company capitalized approximately $0 and $5,188, respectively of MelaFind system costs. Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets (generally three to five years). Costs incurred for maintenance and repairs are expensed as incurred and expenditures for major replacements and improvements are capitalized and depreciated over their estimated remaining useful lives.

Deferred Financing Costs

Financing costs incurred in connection with the 4% Senior Secured Convertible Debentures were deferred and are being amortized over the term of the debentures using the effective interest rate method. As of December 31, 2014 and 2013 the Company recorded deferred financing costs of $821 and $0, respectively.

Long-lived Assets

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition does not exceed its carrying amount. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.

Research and Development

Expenditures for research and development are expensed as incurred.

Accrued Expenses

As part of the process of preparing financial statements, management is required to estimate accrued expenses. This process involves identifying services that have been performed and estimating the level of service performed and the associated cost incurred for such service where it has not been invoiced or otherwise notified of the actual cost. Examples of estimated accrued expenses include:

•

professional service fees;

•

contract clinical and regulatory related service fees;

•

fees paid to contract manufacturers in conjunction with the production of MelaFind components or materials; and

•

fees paid to third party data collection organizations and investigators in conjunction with the clinical trials and FDA and other regulatory review.

In connection with such service fees, management estimates are most affected by projections of the timing of services provided relative to the actual level of services provided by such service providers. In the event that we do not identify certain costs that have begun to be incurred or we under or overestimate the level of services performed or the costs of such services, our actual expenses could differ from such estimates. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services are often subjective determinations. The Company makes these judgments based upon the facts and circumstances known and accrues for such costs in accordance with accounting principles generally accepted in the U.S.

Deferred Rent

Operating lease agreements which contain provisions for future rent increases or periods in which rent payments are reduced or abated are recorded in monthly rent expense in the amount of the total payments over the lease term divided by the number of months of the lease term. The difference between rent expense recorded and the amount paid is credited or charged to deferred rent which is reflected on the accompanying balance sheet.

Stock-Based Compensation

The Company records compensation expense associated with employee stock options, restricted stock awards and other forms of equity compensation in accordance with FASB ASC 718, Compensation-Stock Compensation. The fair value of an equity award is determined at the date of grant using the Black-Scholes Model and the fair value of the equity award is expensed over the service period. The most significant inputs used to value an equity award include current stock price, the amount the employee must pay to acquire the equity award, volatility rate, interest rate and estimated term. For equity awards that vest upon achieving a defined milestone, the underlying compensation charge is recorded when it is probable that the milestone will be achieved. It is then amortized over the estimated period to satisfy vesting requirements. The probability of vesting is updated at each reporting period and compensation is adjusted accordingly. The significant judgments relate to the assumptions used in the valuation model to determine the fair value of the equity instrument including the volatility rate, term and interest rate. Any increases (decreases) in either of the volatility rate, the term or the interest rate would increase (decrease) the value of the equity instrument and the corresponding compensation expense recognized each period. Estimates of performance based awards vesting can also have a significant impact on recognized stock compensation as the likelihood of a performance based award vesting can change from period-to-period with changes in estimates included in current period operations.

Stock-based compensation to non-employee consultants, accounted for pursuant to FASB ASC 505-50 “Equity, Equity Based Payments to Non-Employees”, is granted for services rendered and is completely vested on the grant date. The fair value of the award is determined on the date of grant using the Black-Sholes Model and the fair value is expensed in current period operations.

Income Tax Expense Estimates and Policies

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more-likely-than-not that a tax benefit will not be realized.

With respect to uncertain tax positions, the Company would recognize the tax benefit from an uncertain tax position only if it is more-likely-than-not that the tax position will be sustained upon examination by the taxing authorities, based on the technical merits of the position. The tax benefits to be recognized in the financial statements from such a position would be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. The Company currently has no uncertain tax positions.

The Company does not have any unrecognized tax benefits or accrued penalties and interest. If such matters were to arise, the Company would recognize interest and penalties related to income tax matters in income tax expense. The earliest open tax year subject to examination is 2009.

Net Loss Per Common Share

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of December 31, 2014 and 2013 consist of the following:

	Year Ended December 31,
	2014		2013

Warrants		13,078,920		1,209,361
Convertible debentures		5,228,465		-
Convertible prefered stock		4,595,321		-
Common stock options		1,308,835		306,616
Restricted stock Awards		-		9,941
Total		24,211,541		1,525,918

Comprehensive loss

For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statements of Operations and comprehensive net loss and related per share amounts.

Litigation

From time to time, the Company may become involved in litigation and other legal actions. The Company estimates the range of liability related to any pending litigation where the amount and range of loss can be estimated. The Company records its best estimate of a loss when the loss is considered probable. Where a liability is probable and there is a range of estimated loss with no best estimate in the range, the Company records a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that a liability had been incurred at the date of the financial statements and (ii) the range of loss can be reasonably estimated. Through the date of these financial statements, the Company is not involved in litigation or other legal actions.

Fair Value Measurements

The Company has adopted the provisions of FASB ASC Topic 820, “Fair Value Measurements and Disclosures” as of January 1, 2008 for financial instruments. This standard defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 permits an entity to measure certain financial assets and financial liabilities at fair value with changes in fair value recognized in earnings each period.

Warrant Liability

The Company accounts for the 685,715 common stock warrants issued in connection with the October 31, 2013 financing and 1,329,731 common stock warrants issued in connection with the February 2014 financing in accordance with the guidance contained in ASC 815-40-15-7D, “Contracts in Entity’s Own Equity” whereby under that provision they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company in connection with the financing transactions has been estimated using the Black-Scholes valuation model. The Black-Scholes valuation model was deemed appropriate given the terms of the warrants, and the fact that the key inputs do not change throughout the life of the warrants.

Recently Issued Accounting Standards

In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU” No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for annual periods ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company’s results of operations, cash flows or financial condition.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

Foreign Exchange

The Company’s operations in Germany use the U.S. dollar as its functional currency and from time to time conducts business in Euros. For all periods presented, aggregate foreign exchange transaction gains and losses were not material.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Inventory

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventory

4. Inventory

Inventories currently consist of MelaFind systems; work in process components and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.

During the third quarter of 2014, the Company replaced the Hand-held Imager’s “Field Phantom” imaging test with the “Flap Shutter” imaging test. The new Flap Shutter test utilizes an internal imaging target within each Hand-held Imager. This new test process eliminates the need for the external Field Phantom imaging test fixture; thereby reducing manufacturing material costs, test labor and cycle time. As a result, the Phantom Fixture has become obsolete and $545 was added to the reserve for obsolete inventory.

On August 6, 2014, the Company and Askion GmbH entered into an “Amended and Restated Askion Production Agreement.” This agreement is a mutual settlement and release agreement of two prior unfulfilled purchase orders. The settlement amount of $1,143 was used for inventory purchases which consist primarily of Hand-held Imager assemblies and raw materials.

Throughout 2014, the Company deferred repairs of certain of its MelaFind system units that it determined were unlikely to be sold during the next several periods. The Company estimated the cost to restore its system units to sellable condition and created a repair reserve amounting to $539 at December 31, 2014.

In December 2013, the Company amended its business model for the MelaFind system from solely a rental-based model to include a capital sales option. In accordance with this new model, the Company reclassified $5,402 of MelaFind systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale.

Inventory consists of the following:

	December 31,
	2014		2013
MelaFind Systems	$	3,268	$	5,402
Hand-held Imager assemblies		350		-
Components/raw materials		2,552		-
Accessories		514		554
		6,684		5,956
Reserve for obsolete inventory		(870)		(325)
Reserve for inventory repairs		(539)		-
	$	5,275	$	5,631

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

5. Property and Equipment

In December 2013, the Company amended its business model for the MelaFind system from solely a rental-based to include a capital sales option. In accordance with this new sales model, the Company reclassified $5,402 of MelaFind systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale. Systems that have been leased under the rental-based model remain in property and equipment.

During the year ended December 31, 2014, the Company reclassified $726 of accumulated depreciation related to MelaFind system components that were previously leased and are now available for sale that were included in inventory at December 31, 2013.

Property and equipment, at cost, consists of the following:

	December 31,				Estimated
	2014		2013		Useful Life	Useful Life
Leasehold improvements	$	906	$	906	Lease Term	Lease Term
Laboratory and research equipment		1,084		1,084	3-5 years	3-5 years
Office furniture and equipment		1,969		2,023	3-5 years	3-5 years
MelaFind Systems		3,194		5,081	3 years	3 years
		7,153		9,094
Accumulated depreciation and amortization		(5,192)		(5,403)
	$	1,961	$	3,691

Depreciation expense amounted to approximately $1,785 and $2,434 for the years ended December 31, 2014 and 2013, respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Patents and trademarks

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Patents and trademarks

6. Patents and trademarks

Patents and trademarks as shown in the accompanying balance sheets are net of accumulated amortization of $237 and $232 at December 31, 2014 and 2013, respectively. Amortization expense related to all patents was approximately $5 and $5 for the years ended December 31, 2014 and 2013, respectively. Amortization expense of currently held patents is expected to amount to $5 for each of the years ending December 31, 2015 through 2019, respectively.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. Commitments and Contingencies

The Company is obligated under a non-cancelable operating lease for office, lab, and manufacturing space expiring December 2016. The lease is subject to escalations for increases in operating expenses. For the years ended December 31, the approximate aggregate minimum future payments due under this lease are as follows:

2015	$	478
2016		477

TOTAL	$	955

Rent expense charged to operations amounted to approximately $445 and $509 for the years ended December 31, 2014 and 2013, respectively.

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material in which case we will make separate disclosure as required.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Employee Benefit Plan

12 Months Ended

Dec. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Employee Benefit Plan

8. Employee Benefit Plan

In November 2014, the Company adopted a 401K plan for the benefit of the employees. The Company did not make any contributions to the plan for the year ended December 31, 2014.

In 2013 and prior, the Company had a SIMPLE IRA defined contribution plan covering all qualified employees. An officer of the Company served as trustee of the plan. The Company provided a matching contribution of up to 3% of each employee’s salary. Company contributions to this plan amounted to approximately $136 for the year ended December 31, 2013. On December 31, 2013 the Company ceased contributions and terminated the plan.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References+ Details

Debt

12 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Debt

9. Debt

On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with institutional investors (the “Investors”) providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the “Debentures”), and warrants (the “July 2014 Series A Warrants”) to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share, at an exercise price of $2.45 per share expiring in July 2019. The Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of common stock at an initial conversion price of $2.565 per share (which represents a price above the closing bid price of the common stock on July 18, 2014, the trading day immediately prior to the entry into the Purchase Agreement). The Company’s obligations under the Debentures are secured by a first priority lien on all of the Company’s intellectual property pursuant to the terms of a security agreement (“Security Agreement”) dated July 21, 2014 among the Company and the investors. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of common stock issuable upon conversion of the Series B Preferred Stock and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249). Proceeds from the Debentures are being used for general working capital purposes.

Additionally, in connection with the Purchase Agreement the Company exchanged with certain investors, 12,300 shares of Series A convertible preferred stock issued on February 5, 2014 for 12,300 shares of Series B convertible preferred stock, par value $0.10 and a stated value of $1,000 per share (the “Series B Preferred Stock”), and warrants (the “July 2014 Series B Warrants”) to purchase up to an aggregate of 4,795,321 shares of common stock at an exercise price of $2.45 per share expiring in January 2016. The offering closed on July 24, 2014.

For financial reporting purposes, the $15,000 gross proceeds of the Debentures, was allocated first to the fair value of the obligation to issue the warrants, which totaled $5,296, then to the intrinsic value of the beneficial conversion feature on the Debentures of $4,566.The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the Debentures totaled $10,353 and will be amortized over the five year life of the Debentures. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligations, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. The fair value of the warrant obligation was determined using an option pricing model that used various assumptions including: a stock price of $2.44 per share, volatility of 93.46%, time to maturity of 5.0 years, exercise price of $2.45 per share and a risk free rate of return of 1.62%.

On October 22, 2014, $1,589 worth of Debentures was converted into 619,490 shares of common stock. The resulting debt discount and deferred financing cost adjustment resulted in accelerated interest expense of approximately $1,200.

On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc., a venture capital lender, whereby the Company borrowed $6,000 (“Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules approximately $6,400, including the end of term fee of $425, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty that was defined in the loan documents.

Upon executing the loan documents on March 15, 2013 the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. Accordingly, the Lender received a warrant to purchase 69,321 shares of common stock at an exercise price of approximately $11.18 per share. This warrant will expire on April 26, 2018.

For financial reporting purposes, the $6,000 funded by the Lender on March 15, 2013 was allocated first to the fair value the warrant that totaled approximately $563 and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5,300. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of approximately $90 are included in operating results. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $11.60 to $11.80 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $11.50 to $11.60 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.

The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727. The terms of the Loan included a back-end fee of $425 payable at the maturity of the Loan . The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant at that date was classified within stockholders equity.

Upon repayment of the loan in September 2013, the Company recognized the balance of the unamortized loan discount, fee and deferred financing costs of approximately $983.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Recurring Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Recurring Fair Value Measurements

10. Recurring Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:

•

Level 1: Observable inputs such as quoted prices in active markets;

	•	Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

•

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s financial instruments are cash and cash equivalents, accounts receivable, accounts payable, senior secured convertible debentures and derivative warrant liabilities. The recorded values of cash equivalents, accounts receivable and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of December 31, 2014 and December 31, 2013 is as follows:

Black-Scholes Warrant Pricing	December 31, 2014			December 31, 2013

Stock Price	$	1.20		$	6.40
Risk-free Rate (5-year U.S. Treasury Yield)		1.65	%		1.75	%
Volatility (Annual)		72.90-88.10	%		93.43	%
Time to Maturity (Years)		4.10-4.33			5.33

At December 31, 2014 and December 31, 2013, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Fair Value Measurements at December 31, 2014
	Balance at December 31, 2014		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant derivative liabilities	$	499	$	—	$	—	$	499

Total	$	499	$	—	$	—	$	499

	Fair Value Measurements at December 31, 2013
	Balance at December 31, 2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant derivative liabilities	$	3,017	$	—	$	—	$	3,017

Total	$	3,017	$	—	$	—	$	3,017

The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended December 31, 2014 and 2013:

	Fair Value
	Measurements Using
	Significant
	Unobservable Inputs
	(Level 3)
	Warrant Derivative
	Liabilities
Beginning Balance at January 1, 2013	$	-
Issuance of warrants classified as derivative liabilities		3,373
Changes in estimated fair value		296
Reclassification of derivative liability to additional paid-in capital		(652)
Ending balance at December 31, 2013	$	3,017
Issuance of warrants classified as derivative liabilities		5,585
Changes in estimated fair value		(8,103)
Ending balance at December 31, 2014	$	499

Reclassification of derivative liability to additional paid-in capital relates to the warrants issued in connection with the debt financing that occurred on March 15, 2013. These warrants were accounted for as a liability until such time as the stockholders of the Company approved an increase in the number of authorized shares of the Company’s common stock.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Stockholders' Equity

12. Stockholders’ Equity

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation rights and preferences as may be determined from time to time by the Company’s board of directors. There were 11,787 shares and 0 shares of preferred stock issued and outstanding on December 31, 2014 and December 31, 2013, respectively.

On July 24, 2014, in connection with the offering (see Note 9 “Debt”), the Company exchanged 12,300 shares of its Series A convertible preferred stock issued on February 5, 2014 with 12,300 shares of Series B convertible preferred Stock at a stated value of $1,000 per share convertible into common stock at an initial price of $2.565 per share and July 2014 Series B Warrants to purchase up to an aggregate of 4,795,321 shares of common stock at an exercise price of $2.45 per share, expiring in January 2016. The preferred stock is convertible into an aggregate of 4,795,321 shares of common stock. Holders of the preferred stock are entitled to dividends only in the event that dividends are paid on the common stock, and the preferred stock has no preferences over the common stock, including liquidation rights. The Series B Preferred Stock and the July 2014 Series B Warrants are immediately exercisable and are subject to certain ownership limitations.

For financial reporting purposes, the $12,300 preferred stock value was allocated first to the fair value of the July 2014 Series B warrants, which totaled $2,487, then to the intrinsic value of the beneficial conversion feature of $1,887. The amount of the beneficial conversion feature is considered to be a deemed dividend on the date of issuance to the Series B preferred stockholders due to the July 2014 Series B Warrants being immediately exercisable.

On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share (the “Series A Preferred Stock”), convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and (ii)warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11,458. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014. They will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on December 31, 2014, was approximately $266. The change in fair value of these warrants for the twelve months ended December 30, 2014 was a benefit of $5,319 (see Note 10 “Fair Value of Financial Instruments”).

Pursuant to the terms of the Purchase Agreement, the Series A Convertible Preferred Stock was exchanged for the Series B Convertible Preferred Stock. In September 2014, the Company amended the registration statement related to the Series A Convertible Preferred Stock to deregister those shares that would have been issuable upon conversion of the Series A Convertible Preferred Stock had it not already been redeemed by the proceeds of the Series B Convertible Preferred Stock.

In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3,420.

Common Stock and Warrants

The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share. There were 6,037,232 and 4,750,160 shares of common stock issued and outstanding at December 31, 2014 and December 31, 2013, respectively.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000 registered offering of 422,819 shares of the Company’s common stock, fully paid prefunded Series B Warrants to purchase up to 434,325 shares of its common stock and additional warrants (“October 2013 Series A Warrants”) to purchase up to 685,715 shares of its common stock. The October 2013 Series A Warrants were exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The prefunded Series B Warrants were exercisable immediately for no additional consideration. The October 29, 2013 offering closed on October 31, 2013. The holders exercised all of the prefunded Series B warrants in March 2014. There were no warrant exercises in 2013.

The October 2013 Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. These warrants have been recorded at fair value at the inception date and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The fair value of these warrants on December 31, 2014 and December 31, 2013 was approximately $233 and $3,017, respectively.

The change in fair value of these warrants for the twelve months ended December 31, 2014 and 2013, was a benefit of $2,784 and charge of $206, respectively (see Note 10 “Fair Value of Financial Instruments”).

Outstanding common stock warrants on December 31, 2014 consist of the following:

		Total
Issue Date	Expiration Date	Warrants		Ex. Price
4/26/2013	4/26/2018		69,321	$	11.18
10/31/2013	4/30/2019		685,715	$	8.50
2/5/2014	2/5/2019		1,329,731	$	7.40
7/24/2014	7/24/2019		6,198,832	$	2.45
7/24/2014	1/24/2016		4,795,321	$	2.45
			13,078,920

On August 22, 2013, the Company received a notice from NASDAQ that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

13. Stock-Based Compensation

Stock Options

On April 25, 2013, the Company’s stockholders approved the Company’s adoption of the new 2013 Stock Incentive Plan (“2013 Plan”) having 3,500,000 shares available for issuance in respect of awards made thereunder. The Company terminated the 2005 Stock Incentive Plan in December 2014. As of December 31, 2014, the aggregate number of shares of common stock remaining available for issuance for awards under the 2013 Plan totaled 2,301,691.

Stock awards under the Company’s stock option plans have been granted with exercise prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant. Compensation expense recognized in the Statement of Operations during 2014 and 2013 for stock options and restricted stock awards amounted to $413 and $1,301, respectively. Cash received from options exercised under all share-based payment arrangements for the year ended December 31, 2013 was $18, there were no exercises in 2014.

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation and assumptions as noted in the following table:

	December 31, 2014			December 31, 2013

Expected life		5-10 years			5-10 years
Expected volatility		74-83	%		72-77	%
Risk-free interest rate		1.90-2.45	%		0.71-2.45	%
Dividend yield		-			-

The expected life of the options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. The expected volatility assumptions were determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free rate is based on rates provided by the U.S. Treasury with a term equal to the expected life of the option. The Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

At December 31, 2014, stock options to purchase 1,308,835 shares of common stock at exercise prices ranging from $1.31 to $68.90 per share are outstanding and are exercisable at various dates through 2024. The total number of options exercisable at December 31, 2014 and 2013 was 101,376 and 126,183 respectively, with weighted average exercise prices of $13.45 and $25.60, respectively.

The status of the Company’s stock option plans during the periods indicated is summarized as follows:

					Weighted
					Average
			Weighted		Remaining
			Average		Contractual		Aggregate
	Number of		Exercise		Term in		Intrinsic
	Shares		Price		Years		Value
Outstanding at December 31, 2012		242,654	$	40.10		7.0	$	29
Granted		499,447		14.60		9.5		-
Exercised		(1,806)		10.00				17
Forfeited or expired		(433,679)		27.70				27
Outstanding at December 31, 2013		306,616		16.20		9.0
Granted		1,205,162		1.70		9.4
Exercised		-		-
Forfeited or expired		(202,943)		16.74
Outstanding at December 31, 2014		1,308,835		2.76		9.8
Vested and exercisable at December 31, 2014		101,376	$	13.45		8.4	$	-

During the years ended December 31, 2014 and 2013 the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $1.22 and $6.00 per share, respectively. The total intrinsic value of options exercised during the year ended December 31, 2013 $17, there were no exercises in 2014. The requisite service periods for options granted during 2014 and 2013 for employees was four years and for directors was one year.

The following table summarizes information about stock options outstanding at December 31, 2014:

	Options Outstanding					Options Exercisable
			Weighted-
			Average	Weighted-				Weighted-
			Remaining	Average				Average
	Number		Contractual	Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life	Price		Exercisable		Price
$.01-$3.00		1,125,000	9.95 years	$	1.40		-	$	-
$3.01-$10.00		147,553	8.98 years		6.95		70,443		7.51
$10.01-$70.00		36,282	7.41 years		27.89		30,933		26.97
$.01-$70.00		1,308,835	9.77 years	$	2.76		101,376	$	13.45

As of December 31, 2014, of the total 1,308,835 options outstanding, 1,207,459 have not vested. Of this total unvested amount, 392,425 will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. There was $1,293 of total unrecognized compensation cost related to unvested options, of which approximately $392 will be recognized upon achievement of performance milestones and $901 upon completion of the requisite service period. On February 11, 2013, the Company’s former chief executive officer contractually agreed to not exercise 90,000 fully vested options until such time as the stockholders of the Company approved an increase in the number of authorized shares of the Company’s common stock, or, if earlier, the Company’s written consent. On April 25, 2013, the Company’s stockholders approved an increase in the authorized shares of common stock and therefore the restriction placed on the former CEO’s ability to exercise the 90,000 fully vested options lapsed. For financial reporting purposes, the Forbearance Agreement was accounted for at the time it was executed as a cancellation with no concurrent grant and therefore upon the lapsing of the exercise restriction on April 25, 2013, the Company recognized additional stock compensation of approximately $423.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Related Party Agreements

12 Months Ended

Dec. 31, 2014

Related Party Agreements

15. Related Party Agreements

Gravitas Healthcare LLC

Mr. Samuel E. Navarro, a member of the Company’s Board of Directors and managing partner of Gravitas Healthcare LLC, received $86 of a placement fee paid by the Company to Gravitas for services rendered in connection with the sale of the Company’s Series A Convertible Preferred Stock completed in February 2014.

Transition Services Provided by Robert Coradini

On March 11, 2014, the Company agreed to pay Robert Coradini, a director and the Company’s former Interim Chief Executive Officer, approximately $48 in consideration for services provided in connection with the transition to a new Chief Executive Officer during the fourth quarter of 2013.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

16. Income Taxes

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company has incurred net losses since inception, accordingly, it has not provided for income taxes for the years ended December 31, 2014 and 2013.

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the years ended December 31,
	2014		2013
Computed expected tax benefit	$	(4,270)	$	(8,822)
State tax benefit, net of federal effect		(217)		(1,557)
Increase in the valuation allowance		4,487		10,379
Provision for income taxes	$	-	$	-

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:

	December 31,
	2014		2013
Deferred tax assets:
Net operating loss carryforward	$	57,367	$	35,086
Capitalized research and developmental costs		12,925		27,794
Inventory		689		-
Reserves & accrued expenses		135		-
Warrant Liability		(3,123)		-
Property & equipment		(785)		-
Non-cash compensation		3,840		3,681
Total deferred tax assets		71,048		66,561
Less valuation allowance		(71,048)		(66,561)
Net deferred tax assets	$	-	$	-

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on the Company’s historical net losses, management does not believe that it is more-likely-than not that the Company will realize the benefits of these deferred tax assets and, accordingly, a full valuation allowance has been recorded against the deferred tax assets as of December 31, 2014 and 2013. The Company’s valuation allowance against its deferred tax assets increased by $4,487 and $10,379 for the years ended December 31, 2014 and 2013, respectively.

At December 31, 2014, the Company has federal net operating loss carryforwards of approximately $144,759 to offset future taxable income. The Company has experienced certain ownership changes which, under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company’s ability to utilize its net operating losses in the future. The February 2014 and July 2014 equity raises by the Company, will likely limit the annual use of these net operating loss carryforwards.

FASB ASC 740 “Income Taxes” contains guidance with respect to uncertain tax positions which applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to recognize. Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Restructuring Charge

12 Months Ended

Dec. 31, 2014

Restructuring and Related Activities [Abstract]

Restructuring Charge

17. Restructuring Charge

As discussed in Note 1, in response to recurring operating losses and limited liquidity, the Company’s Board of Directors approved the Cost Reduction Plan that included a reduction in work force, the prospective elimination or deferral of all nonessential projects and activities and the scaling back or discontinuance of general corporate activities. The communication to affected employees was made during August 2013. In connection therewith, the Company recorded a charge for employee termination benefits totaling approximately $100 in the third quarter of 2013 that is reflected in the statement of operations as increases in cost of revenue, research and development and selling, general and administrative expenses. As of December 31, 2014 substantially all termination benefits have been paid.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Liquidity and Going Concern

Liquidity and Going Concern

Cash and cash equivalents

Cash and Cash Equivalents

Use of Estimates

Use of Estimates

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

Inventories

Inventories

Business Segments

Business Segments

The Company’s operations are confined to one business segment: the design, development and commercialization of the MelaFind system.

Revenue recognition

Revenue recognition

Cost of Revenue

Cost of Revenue

Property and Equipment

Property and Equipment

Deferred Financing Costs

Deferred Financing Costs

Long-lived Assets

Long-lived Assets

Research and Development

Research and Development

Expenditures for research and development are expensed as incurred.

Accrued Expenses

Accrued Expenses

•

professional service fees;

•

contract clinical and regulatory related service fees;

•

fees paid to contract manufacturers in conjunction with the production of MelaFind components or materials; and

•

fees paid to third party data collection organizations and investigators in conjunction with the clinical trials and FDA and other regulatory review.

Deferred Rent

Deferred Rent

Stock-Based Compensation

Stock-Based Compensation

Income Tax Expense Estimates and Policies

Income Tax Expense Estimates and Policies

The Company accounts for income taxes using the asset and liability method for deferred income taxes.

Net Loss Per Common Share

Net Loss Per Common Share

	Year Ended December 31,
	2014		2013

Warrants		13,078,920		1,209,361
Convertible debentures		5,228,465		-
Convertible prefered stock		4,595,321		-
Common stock options		1,308,835		306,616
Restricted stock Awards		-		9,941
Total		24,211,541		1,525,918

Comprehensive loss

Comprehensive loss

Litigation

Litigation

Fair Value Measurements

Fair Value Measurements

Warrant Liability

Warrant Liability

Recently Issued Accounting Standards

Recently Issued Accounting Standards

Foreign Exchange

Foreign Exchange

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment

Property and equipment, at cost, consists of the following:

	December 31,				Estimated
	2014		2013		Useful Life	Useful Life
Leasehold improvements	$	906	$	906	Lease Term	Lease Term
Laboratory and research equipment		1,084		1,084	3-5 years	3-5 years
Office furniture and equipment		1,969		2,023	3-5 years	3-5 years
MelaFind Systems		3,194		5,081	3 years	3 years
		7,153		9,094
Accumulated depreciation and amortization		(5,192)		(5,403)
	$	1,961	$	3,691

Recurring Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Disclosures [Abstract]

Summary of Quantitative Information with Respect to Valuation Methodology and Significant Unobservable Inputs Used for Company's Warrant Liabilities

Black-Scholes Warrant Pricing	December 31, 2014			December 31, 2013

Stock Price	$	1.20		$	6.40
Risk-free Rate (5-year U.S. Treasury Yield)		1.65	%		1.75	%
Volatility (Annual)		72.90-88.10	%		93.43	%
Time to Maturity (Years)		4.10-4.33			5.33

Estimated Fair Values of Liabilities Measured on Recurring Basis

At December 31, 2014 and December 31, 2013, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Fair Value Measurements at December 31, 2014
	Balance at December 31, 2014		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant derivative liabilities	$	499	$	—	$	—	$	499

Total	$	499	$	—	$	—	$	499

	Fair Value Measurements at December 31, 2013
	Balance at December 31, 2013		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant derivative liabilities	$	3,017	$	—	$	—	$	3,017

Total	$	3,017	$	—	$	—	$	3,017

Liabilities Measured at Estimated Fair Value Using Unobservable Inputs

The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the years ended December 31, 2014 and 2013:

	Fair Value
	Measurements Using
	Significant
	Unobservable Inputs
	(Level 3)
	Warrant Derivative
	Liabilities
Beginning Balance at January 1, 2013	$	-
Issuance of warrants classified as derivative liabilities		3,373
Changes in estimated fair value		296
Reclassification of derivative liability to additional paid-in capital		(652)
Ending balance at December 31, 2013	$	3,017
Issuance of warrants classified as derivative liabilities		5,585
Changes in estimated fair value		(8,103)
Ending balance at December 31, 2014	$	499

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References+ Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Schedule of Outstanding Common Stock Warrants

Outstanding common stock warrants on December 31, 2014 consist of the following:

		Total
Issue Date	Expiration Date	Warrants		Ex. Price
4/26/2013	4/26/2018		69,321	$	11.18
10/31/2013	4/30/2019		685,715	$	8.50
2/5/2014	2/5/2019		1,329,731	$	7.40
7/24/2014	7/24/2019		6,198,832	$	2.45
7/24/2014	1/24/2016		4,795,321	$	2.45
			13,078,920

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation and assumptions as noted in the following table:

	December 31, 2014			December 31, 2013

Expected life		5-10 years			5-10 years
Expected volatility		74-83	%		72-77	%
Risk-free interest rate		1.90-2.45	%		0.71-2.45	%
Dividend yield		-			-

Schedule of Stock Option Plans

The status of the Company’s stock option plans during the periods indicated is summarized as follows:

					Weighted
					Average
			Weighted		Remaining
			Average		Contractual		Aggregate
	Number of		Exercise		Term in		Intrinsic
	Shares		Price		Years		Value
Outstanding at December 31, 2012		242,654	$	40.10		7.0	$	29
Granted		499,447		14.60		9.5		-
Exercised		(1,806)		10.00				17
Forfeited or expired		(433,679)		27.70				27
Outstanding at December 31, 2013		306,616		16.20		9.0
Granted		1,205,162		1.70		9.4
Exercised		-		-
Forfeited or expired		(202,943)		16.74
Outstanding at December 31, 2014		1,308,835		2.76		9.8
Vested and exercisable at December 31, 2014		101,376	$	13.45		8.4	$	-

Schedule of Stock Options Outstanding

The following table summarizes information about stock options outstanding at December 31, 2014:

	Options Outstanding					Options Exercisable
			Weighted-
			Average	Weighted-				Weighted-
			Remaining	Average				Average
	Number		Contractual	Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life	Price		Exercisable		Price
$.01-$3.00		1,125,000	9.95 years	$	1.40		-	$	-
$3.01-$10.00		147,553	8.98 years		6.95		70,443		7.51
$10.01-$70.00		36,282	7.41 years		27.89		30,933		26.97
$.01-$70.00		1,308,835	9.77 years	$	2.76		101,376	$	13.45

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Computation of U.S. Federal Income Tax Rate to Pretax Loss From Continuing Operations

The difference between the actual income tax benefit and that computed by applying the U.S. federal income tax rate of 34% to pretax loss from continuing operations is summarized below:

	For the years ended December 31,
	2014		2013
Computed expected tax benefit	$	(4,270)	$	(8,822)
State tax benefit, net of federal effect		(217)		(1,557)
Increase in the valuation allowance		4,487		10,379
Provision for income taxes	$	-	$	-

Summary of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:

	December 31,
	2014		2013
Deferred tax assets:
Net operating loss carryforward	$	57,367	$	35,086
Capitalized research and developmental costs		12,925		27,794
Inventory		689		-
Reserves & accrued expenses		135		-
Warrant Liability		(3,123)		-
Property & equipment		(785)		-
Non-cash compensation		3,840		3,681
Total deferred tax assets		71,048		66,561
Less valuation allowance		(71,048)		(66,561)
Net deferred tax assets	$	-	$	-

Basis of Presentation - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended		12 Months Ended
	Jul. 31, 2014	Feb. 28, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Proceeds From Issuance Of Common Stock And Warrant		$ 11,458
Proceeds From Sale Of Convertible Preferred Stock Common Stock And Warrants	15,000
Accumulated deficit			182,293	168,148
Net Income (Loss) Attributable to Parent			(14,145)	(25,948)
Working Capital			14,517
Cash and cash equivalents			$ 11,434	$ 3,783	$ 7,862

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 28, 2014	Dec. 31, 2013	Oct. 31, 2013
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Liquid investment maturity period	Three months or less
Reserve for obsolete inventory	$ 1,409,000		$ 325,000
Number of segments operated by the company	1
Associated revenue over the related service period	Generally expected to be two years
Deferred financing costs	821,000		0
Uncertain tax positions	0
Tax benefits to be recognized on likelihood of being realized upon ultimate resolution	Greater than fifty percent
Open tax year subject to examination	2009
Comprehensive income (loss)	0
Warrants issued to purchase common stock				685,715
Inventory Valuation Reserves	539,000
Class of Warrant or Right, Outstanding	13,078,920	1,329,731
Maximum [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of related assets	5 years
Minimum [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of related assets	3 years
Mela Find Systems [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment, capitalization cost	0		5,188,000
Obsolete Inventory [Member]
Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Reserve for obsolete inventory	870
Inventory Valuation Reserves	$ 870,000		$ 325,000

Summary of Significant Accounting Policies - Schedule of Stock Options, Warrants and Restricted Stock Awards (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	24,211,541	1,525,918
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	0	9,941
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	1,308,835	306,616
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	4,595,321	0
Convertible Debentures [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	5,228,465	0
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Potential common stock equivalents	13,078,920	1,209,361

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Inventory - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Aug. 06, 2014	Dec. 31, 2013
Inventory [Line Items]
Inventory, Gross	$ 6,684		$ 5,956
Reserve for inventory	539
Mela Find Systems [Member]
Inventory [Line Items]
Inventory, Gross	3,268		5,402
Hand Held Imager Assemblies [Member]
Inventory [Line Items]
Inventory, Gross	350		0
Settlement amount		1,143
Inventory Repairs [Member]
Inventory [Line Items]
Reserve for inventory	$ 539		$ 0

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Inventory - Schedule of Inventory (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Inventory, Gross	$ 6,684	$ 5,956
Inventory Valuation Reserves	(539)
Inventory, Net	5,275	5,631
Hand Held Imager Assemblies [Member]
Inventory [Line Items]
Inventory, Gross	350	0
Obsolete Inventory [Member]
Inventory [Line Items]
Inventory Valuation Reserves	(870)	(325)
Accessories [Member]
Inventory [Line Items]
Inventory, Gross	514	554
Components/raw materials [Member]
Inventory [Line Items]
Inventory, Gross	2,552	0
Mela Find Systems [Member]
Inventory [Line Items]
Inventory, Gross	3,268	5,402
Inventory Repairs [Member]
Inventory [Line Items]
Inventory Valuation Reserves	$ (539)	$ 0

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Property and Equipment - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Inventory, Gross	$ 6,684	$ 5,956
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	5,192	5,403
Depreciation	1,785	2,434
Mela Find Systems [Member]
Property, Plant and Equipment [Line Items]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	726
Components [Member] \| Mela Find Systems [Member]
Property, Plant and Equipment [Line Items]
Inventory, Gross		$ 5,402

Property and Equipment - Summary of Property and Equipment (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Gross	$ 7,153	$ 9,094
Accumulated depreciation and amortization	(5,192)	(5,403)
Net	1,961	3,691
Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross	906	906
Estimated Useful Life	Lease Term
Laboratory and Research Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	1,084	1,084
Laboratory and Research Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Useful Life	5 years
Laboratory and Research Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Useful Life	3 years
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross	1,969	2,023
Office Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Useful Life	5 years
Office Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Life	3 years
Useful Life	3 years
MelaFind Systems [Member]
Property, Plant and Equipment [Line Items]
Gross	3,194	5,081
Accumulated depreciation and amortization	$ (726)
Estimated Useful Life	3 years
Useful Life	3 years

Patents and Trademarks - Additional Information (Detail) (Patents and Trademarks [Member], USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization, net	$ 237	$ 232
Amortization expense related to all patents	5	5
Amortization expense of currently held patents for the year 2015	5
Amortization expense of currently held patents for the year 2016	5
Amortization expense of currently held patents for the year 2017	5
Amortization expense of currently held patents for the year 2018	5
Amortization expense of currently held patents for the year 2019	$ 5

Commitments and Contingencies - Schedule of Approximate Aggregate Minimum Future Payments (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2015	$ 478
2016	477
TOTAL	$ 955

Debt - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended		1 Months Ended	12 Months Ended				12 Months Ended			0 Months Ended		0 Months Ended		1 Months Ended	0 Months Ended	12 Months Ended					12 Months Ended
	Jul. 21, 2014	Sep. 10, 2013	Oct. 22, 2014	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2013	Mar. 15, 2013	Dec. 31, 2014 Maximum [Member]	Dec. 31, 2014 Minimum [Member]	Dec. 31, 2014 Option Pricing Model [Member]	Mar. 15, 2013 Hercules Technology Growth Capital Inc [Member]	Sep. 10, 2013 Hercules Technology Growth Capital Inc [Member]	Jul. 21, 2014 Series A Warrants [Member]	Oct. 29, 2013 Series A Warrants [Member]	Jul. 24, 2014 Series B Warrants [Member]	Jul. 21, 2014 Series B Preferred Stock [Member]	Dec. 31, 2014 Series B Preferred Stock [Member]	Dec. 31, 2013 Series B Preferred Stock [Member]	Feb. 05, 2014 Series B Preferred Stock [Member]	Dec. 31, 2014 Debentures [Member]	Jul. 21, 2014 Debentures [Member]	Dec. 31, 2014 Warrant Obligation [Member]	Dec. 31, 2014 Warrant Obligation [Member] Maximum [Member]	Dec. 31, 2014 Warrant Obligation [Member] Minimum [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Shares, New Issues																	12,300,000	0
Preferred Stock, Par or Stated Value Per Share				$ 0.10	$ 0.10														$ 1,000.00
Preferred Stock Stated Value Per Share																			$ 0.10
Proceeds from Issuance of Debt	$ 15,000
Warrants Issued to Purchase Common Stock, Shares													6,198,832		4,795,321
Common Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001								$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 11.18		$ 2.45	$ 8.50	$ 2.45
Investment Warrants Expiration Month and Year													2019-07		2016-01	2019-07
Debt Instrument, Interest Rate, Stated Percentage											10.45%									4.00%
Debt Conversion, Converted Instrument, Shares Issued	5,847,955		619,490
Convertible Preferred Stock Initial Conversion Price	$ 2.565
Fair Value of Warrant Obligation	5,296						563
Debt Instrument, Convertible, Beneficial Conversion Feature	4,566			4,565	0
Fair Value of Warrants Issued	491
Senior Notes, Noncurrent	4,647
Debt Instrument, Unamortized Discount				8,410																	10,353	727
Share Price										$ 2.44													$ 11.80	$ 11.60
Fair Value Assumptions, Expected Volatility Rate					93.43%			88.10%	72.90%	93.46%												77.00%
Fair Value Assumptions, Expected Term					5 years 3 months 29 days			4 years 3 months 29 days	4 years 1 month 6 days	5 years												5 years
Fair Value Assumptions, Exercise Price				$ 1.20	$ 6.40					$ 2.45													$ 11.60	$ 11.50
Fair Value Assumptions, Risk Free Interest Rate				1.65%	1.75%					1.62%												0.84%
Debt and Capital Lease Obligations											6,000
Borrowed Funds Maturity Period											42 months
Debt Instrument Period of Initial Interest Payment											first 12 months
Prepayment of Loan												6,400
Debt Instrument, Fee Amount												425
Aggregate Consideration Receivable For Warrants To Be Issued						685,715					69,321			685,715
Investment Warrants Expiration Date											Apr. 26, 2018
Long-term Debt, Gross							5,300
Fair Value Adjustment of Warrants				2,784	206																	90
Percentage of Change in Unobservable Input																						10.00%
Gains (Losses) on Extinguishment of Debt		983
Debt Conversion, Converted Instrument, Amount			1,589		652													0
Interest Expense, Debt			$ 1,200

Recurring Fair Value Measurements - Summary of Quantitative Information with Respect to Valuation Methodology and Significant Unobservable Inputs Used for Company's Warrant Liabilities (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock Price	$ 1.20	$ 6.40
Risk-free Rate (5-year U.S. Treasury Yield)	1.65%	1.75%
Volatility (Annual)		93.43%
Time to Maturity (Years)		5 years 3 months 29 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility (Annual)	88.10%
Time to Maturity (Years)	4 years 3 months 29 days
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility (Annual)	72.90%
Time to Maturity (Years)	4 years 1 month 6 days

Recurring Fair Value Measurements - Estimated Fair Values of Liabilities Measured on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 499	$ 3,017
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	499	3,017
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	0	0
Quoted Prices in Active Markets (Level 1) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	0	0
Significant Other Observable Inputs (Level 2) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	499	3,017
Significant Unobservable Inputs (Level 3) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	$ 499	$ 3,017	$ 0

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References+ Details

Recurring Fair Value Measurements - Liabilities Measured at Estimated Fair Value Using Unobservable Inputs (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending balance	$ 499	$ 3,017
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending balance	499	3,017
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ending balance	499	3,017
Significant Unobservable Inputs (Level 3) [Member] \| Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	3,017	0
Issuance of warrants classified as derivative liabilities	5,585	3,373
Changes in estimated fair value	(8,103)	296
Reclassification of derivative liability to additional paid-in capital		(652)
Ending balance	$ 499	$ 3,017

- Definition

+ References+ Details

Stockholders' Equity - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended				12 Months Ended			1 Months Ended		12 Months Ended				0 Months Ended	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 21, 2014	Oct. 31, 2013	Dec. 31, 2014 Series B [Member]	Jul. 24, 2014 Series B Prefunded Warrants [Member]	Oct. 29, 2013 Series B Prefunded Warrants [Member]	Jul. 24, 2014 Convertible Preferred Stock [Member]	Jul. 24, 2014 Convertible Preferred Stock [Member] Series B [Member]	Dec. 31, 2014 Series B Preferred Stock [Member]	Dec. 31, 2013 Series B Preferred Stock [Member]	Jul. 24, 2014 Series B Preferred Stock [Member]	Feb. 05, 2014 Series B Preferred Stock [Member]	Feb. 05, 2014 Common Stock Equivalents of Convertible Preferred Stock [Member]	Dec. 31, 2014 Common Stock Equivalents of Convertible Preferred Stock [Member]	Dec. 31, 2014 Series B Warrants [Member]	Jul. 24, 2014 Series B Warrants [Member]	Oct. 29, 2013 Series A Warrants [Member]	Jul. 21, 2014 Series A Warrants [Member]
Securities Financing Transaction [Line Items]
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.10	$ 0.10											$ 1,000.00	$ 1,000.00
Preferred Stock, Shares Issued	11,787	0												12,300
Preferred Stock, Shares Outstanding	11,787	0
Stock Issued During Period, Shares, New Issues								12,300,000	12,300	12,300,000	0
Preferred Stock Stated Value Per Share									$ 1,000.00				$ 0.10	$ 0.10
Convertible Preferred Stock Initial Conversion Price			$ 2.565						$ 2.565					$ 8.40
Warrants Issued to Purchase Common Stock, Shares						4,795,321								1,329,731			4,795,321		6,198,832
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.45								$ 7.40			$ 2.45	$ 8.50	$ 2.45
Convertible Preferred Stock, Shares Issued upon Conversion												4,795,321		1,464,287
Preferred Stock, Value, Issued	$ 1	$ 0														$ 12,300
Stock Issued During Period, Value, Conversion of Convertible Securities	0				2,487					0
Convertible Preferred Stock Converted to Other Securities	1,887
Proceeds from Issuance of Warrants														11,458
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	233	3,017													266
Fair Value Adjustment of Warrants	2,784	206													5,319
Registration Rights Liquidating Damages	3,420	0
Proceeds From Borrowings And Warrant Exercises																		$ 6,000
Common Stock, Shares Authorized	50,000,000	50,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001																	$ 0.001
Common Stock, Shares, Issued	6,037,232	4,750,160																422,819
Common Stock, Shares, Outstanding	6,037,232	4,750,160
Aggregate Consideration Receivable For Warrants To Be Issued				685,715			434,325											685,715

Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail) (USD $)			12 Months Ended
	Dec. 31, 2014	Feb. 28, 2014	Dec. 31, 2014 Ex. Price $ 11.18 [Member]	Dec. 31, 2014 Ex. Price $ 8.50 [Member]	Dec. 31, 2014 Ex. Price $ 7.40 [Member]	Dec. 31, 2014 Ex. Price $ 2.45 [Member]	Dec. 31, 2014 Ex. Price $ 2.45 [Member]
Class of Warrant or Right [Line Items]
Issue Date			Apr. 26, 2013	Oct. 31, 2013	Feb. 05, 2014	Jul. 24, 2014	Jul. 24, 2014
Expiration Date			Apr. 26, 2018	Apr. 30, 2019	Feb. 05, 2019	Jul. 24, 2019	Jan. 24, 2016
Total Warrants	13,078,920	1,329,731	69,321	685,715	1,329,731	6,198,832	4,795,321
Ex. Price			$ 11.18	$ 8.50	$ 7.40	$ 2.45	$ 2.45

Stock-Based Compensation - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Apr. 25, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 11, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry period of option plan		10 years
Compensation expense recognized for stock option		$ 413,000	$ 1,301,000
Cash received from options and warrants exercised			18,000
Number of stock options to purchase		1,308,835
Common stock at exercise prices range, minimum		$ 1.31
Common stock at exercise prices range, maximum		$ 68.90
Total options outstanding		101,376	126,183
Weighted Average Exercise Price per Share Vested and exercisable		$ 13.45	$ 25.60
Weighted average fair value of options granted		$ 1.22	$ 6.00
Total intrinsic value of options exercised		0	17,000
Requisite service periods for options granted for employees		4 years	4 years
Requisite service periods for options granted to directors		1 year	1 year
Total options outstanding		1,308,835	306,616		242,654
Options nonvested		1,207,459
Total unrecognized compensation cost related to unvested options		1,293,000
Total unrecognized compensation cost to be recognized over the requisite service period		901,000
Fully vested options				90,000
Fully vested options lapsed	90,000
Fully vested options lapsing exercise restriction date		Apr. 25, 2013
Additional stock compensation recognized	423,000
2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grants	3,500,000
2005 and 2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate shares of common stock available for grant		2,301,691
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vested upon the attainment of milestone		392,425
Total unrecognized compensation cost		$ 392,000

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility - Minimum	74.00%	72.00%
Expected volatility - Maximum	83.00%	77.00%
Risk-free interest rate - Minimum	1.90%	0.71%
Risk-free interest rate - Maximum	2.45%	2.45%
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	5 years	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	10 years	10 years

Stock-Based Compensation - Schedule of Stock Option Plans (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares Outstanding, Beginning of the period	306,616	242,654
Number of Shares Granted	1,205,162	499,447
Number of Shares Exercised	0	(1,806)
Number of Shares Forfeited or expired	(202,943)	(433,679)
Number of Shares Outstanding, Ending of the period	1,308,835	306,616	242,654
Number of Shares Vested and exercisable	101,376
Weighted Average Exercise Price per Share Outstanding, Beginning of the period	$ 16.20	$ 40.10
Weighted Average Exercise Price per Share Granted	$ 1.70	$ 14.60
Weighted Average Exercise Price per Share of options Exercised	$ 0	$ 10.00
Weighted Average Exercise Price per Share Forfeited or expired	$ 16.74	$ 27.70
Weighted Average Exercise Price per Share Outstanding, Ending of the period	$ 2.76	$ 16.20	$ 40.10
Weighted Average Exercise Price per Share Vested and exercisable	$ 13.45	$ 25.60
Weighted Average Remaining Contractual Term in Years Granted	9 years 4 months 24 days	9 years 6 months
Weighted Average Remaining Contractual Term in Years Vested and exercisable	8 years 4 months 24 days
Weighted Average Remaining Contractual Term in Years Outstanding	9 years 9 months 18 days	9 years	7 years
Aggregate Intrinsic Value Outstanding (in dollars)		$ 29
Aggregate Intrinsic Value for Granted (in dollars)		0
Aggregate Intrinsic Value for Exercised (in dollars)		17
Aggregate Intrinsic Value for Forfeited or expired (in dollars)		27
Aggregate Intrinsic Value Outstanding Vested and exercisable (in dollars)	$ 0

Stock-Based Compensation - Schedule of Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 1.31
Range of Exercise Prices, Upper Range Limit	$ 68.90
Options Exercisable, Number Exercisable	1,308,835
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 0.01
Range of Exercise Prices, Upper Range Limit	$ 3.00
Options Outstanding, Number Outstanding	1,125,000
Options Outstanding, Weighted-Average Remaining Contractual Life (in years)	9 years 11 months 12 days
Options Outstanding, Weighted-Average Exercise Price (in dollars per share)	$ 1.40
Options Exercisable, Number Exercisable	0
Options Exercisable, Weighted-Average Exercise Price (in dollars per share)	$ 0
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 3.01
Range of Exercise Prices, Upper Range Limit	$ 10.00
Options Outstanding, Number Outstanding	147,553
Options Outstanding, Weighted-Average Remaining Contractual Life (in years)	8 years 11 months 23 days
Options Outstanding, Weighted-Average Exercise Price (in dollars per share)	$ 6.95
Options Exercisable, Number Exercisable	70,443
Options Exercisable, Weighted-Average Exercise Price (in dollars per share)	$ 7.51
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 10.01
Range of Exercise Prices, Upper Range Limit	$ 70.00
Options Outstanding, Number Outstanding	36,282
Options Outstanding, Weighted-Average Remaining Contractual Life (in years)	7 years 4 months 28 days
Options Outstanding, Weighted-Average Exercise Price (in dollars per share)	$ 27.89
Options Exercisable, Number Exercisable	30,933
Options Exercisable, Weighted-Average Exercise Price (in dollars per share)	$ 26.97
Net Range [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	$ 0.01
Range of Exercise Prices, Upper Range Limit	$ 70.00
Options Outstanding, Number Outstanding	1,308,835
Options Outstanding, Weighted-Average Remaining Contractual Life (in years)	9 years 9 months 7 days
Options Outstanding, Weighted-Average Exercise Price (in dollars per share)	$ 2.76
Options Exercisable, Number Exercisable	101,376
Options Exercisable, Weighted-Average Exercise Price (in dollars per share)	$ 13.45

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
U.S. federal income tax rate	34.00%
Increase in the valuation allowance	$ 4,487	$ 10,379
Net operating loss carryforwards	$ 144,759
Tax benefit recognition, description	Tax positions that meet the more likely than not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority.

Income Taxes - Computation of U.S. Federal Income Tax Rate to Pretax Loss From Continuing Operations (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Computed expected tax benefit	$ (4,270)	$ (8,822)
State tax benefit, net of federal effect	(217)	(1,557)
Increase in the valuation allowance	4,487	10,379
Provision for income taxes	$ 0	$ 0

Income Taxes - Summary of Deferred Tax Assets and Liabilities (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforward	$ 57,367	$ 35,086
Capitalized research and developmental costs	12,925	27,794
Inventory	689	0
Reserves & accrued expenses	135	0
Warrant Liability	(3,123)	0
Property & equipment	(785)	0
Non-cash compensation	3,840	3,681
Total deferred tax assets	71,048	66,561
Less valuation allowance	(71,048)	(66,561)
Net deferred tax assets	$ 0	$ 0

Subsequent Event - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014
Subsequent Event [Line Items]
Conversion of Stock, Amount Converted	$ 12,300
Subsequent Event [Member] \| Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Conversion of Stock, Amount Converted	1,508
Conversion of Stock, Shares Issued	587,915
Long-term Debt [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Conversion, Original Debt, Amount	$ 2,308
Debt Conversion, Converted Instrument, Shares Issued	899,999

Commitments and Contingencies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Other Commitments [Line Items]
Non-cancelable operating lease expiry period	2016-12
Rent expense charged to operations	$ 445	$ 509

Employee Benefit Plan - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer	$ 136
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%

Reverse Split of Common Stock - Additional Information (Detail)	0 Months Ended
	Jul. 09, 2014
Class of Stock [Line Items]
Stockholders' Equity, Reverse Stock Split	The reverse split took effect at the start of trading on July10, 2014 on a 1-for-10 split basis.

Related Party Agreements - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	0 Months Ended	12 Months Ended
	Mar. 11, 2014 Transition Services Provided By Robert Coradini [Member]	Dec. 31, 2014 Director [Member]
Related Party Transaction [Line Items]
Placement fee		$ 86
Service fee	$ 48

Restructuring Charge - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]
Employee termination benefits	$ 100

Recurring Fair Value Measurements - Summary of Quantitative Information with Respect to Valuation Methodology and Significant Unobservable Inputs Used for Company's Warrant Liabilities (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
U.S Treasury Yield, period	5 years

Other Income - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Other Income And Expenses [Line Items]
Royalties earned	$ 149	$ 20